Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colchimax is an oral pharmaceutical drug that combines two active ingredients: colchicine and dicycloverine. It is primarily indicated for the treatment and prevention of acute gout attacks, chronic gout, and familial Mediterranean fever. Colchicine, an alkaloid, exerts its therapeutic effects by inhibiting microtubule polymerization, which in turn disrupts inflammasome activation, inflammatory cell chemotaxis, and the production of pro-inflammatory mediators like leukotrienes and cytokines. This leads to a significant anti-inflammatory action, particularly by reducing neutrophil motility and activity. Dicycloverine, an anticholinergic agent, is included to mitigate gastrointestinal side effects often associated with colchicine, such as diarrhea, by blocking acetylcholine at muscarinic receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Colchimax.